Analysed INTELLIA THERAPEUTICS INC (NTLA:NASDAQ) News Sources
Intellia Therapeutics to Present at Morgan Stanley 24th Annual Global Healthcare Conference
04-09-2026
yahoo.com
Intellia Therapeutics Secures Non-Dilutive Debt Facility with OrbiMed for up to $400 Million
04-09-2026
yahoo.com
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04-09-2026
yahoo.com
Should Intellia’s Milestone-Linked OrbiMed Loan Reshape Funding Risk Perceptions For Intellia Therapeutics (NTLA) Investors?
05-09-2026
yahoo.com
Intellia Therapeutics (NTLA) Secures $400 Million As Investors Ask If The Upside Is Priced In
05-09-2026
yahoo.com
Intellia Therapeutics Announces FDA Acceptance of Biologics License Application with Priority Review for Lonvoguran Ziclumeran (Lonvo-z) for Hereditary Angioedema (HAE)
08-09-2026
yahoo.com
Cathie Wood’s Biotech Bet Intellia Secured An FDA Priority Review For Rare Genetic Disorder Therapy – Retail Sees Upside In NTLA’s Platform
08-09-2026
stocktwits.com
What is the current price of INTELLIA THERAPEUTICS INC (NTLA:NASDAQ)?
The current price of INTELLIA THERAPEUTICS INC (NTLA:NASDAQ) is $11.73.
INTELLIA THERAPEUTICS INC (NTLA:NASDAQ) absolute price change since previous trading day?
The absolute price change of INTELLIA THERAPEUTICS INC (NTLA:NASDAQ) since the previous trading day is $-0.2.
INTELLIA THERAPEUTICS INC (NTLA:NASDAQ) percentage price change since previous trading day?
The percentage price change of INTELLIA THERAPEUTICS INC (NTLA:NASDAQ) since the previous trading day is -1.6764%.
What is the most recent average sentiment score for INTELLIA THERAPEUTICS INC (NTLA:NASDAQ)?
The most recent average sentiment score for INTELLIA THERAPEUTICS INC (NTLA:NASDAQ) is 78 out of 100.
What is the most recent average sentiment for INTELLIA THERAPEUTICS INC (NTLA:NASDAQ)?
The most recent sentiment for INTELLIA THERAPEUTICS INC (NTLA:NASDAQ) is .
SEC-8K** Filing Available For INTELLIA THERAPEUTICS INC (NTLA:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.